In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Greg Plunkett, Founder and CEO of Accelagen.

Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Greg, covering:

How years at big pharma exposed him to the full journey from concept to commercialisation.
Why stepping into a smaller organisation gave him the practical tools and confidence to start his own venture.
How following market signals into regulatory consulting, while being a stay at home dad, became the foundation for Accelagen.
Why trust, referrals and long term relationships have driven sustainable growth.
How Australia’s clinical trial ecosystem offers quality, speed and tax advantages that attract global innovators.
What it takes to guide small to mid sized biotech companies from discovery all the way to market.

Greg Plunkett is the Founder and CEO of Accelagen, a full service regulatory affairs and clinical development CRO headquartered in Melbourne, Australia. His career spans almost 30 years across both big and small pharma and biotech organisations before founding Accelagen in 2010. He has supported local and international companies in developing new technologies from discovery through to commercialisation.

Greg leads a highly experienced team across Australia, New Zealand and the United States, united by a mission to make a meaningful difference to the future of human health.

He holds a Masters of Medical Science from the University of New South Wales and postgraduate business qualifications.

Molecule to Market is also sponsored by Bora Pharmaceuticals and supported by Lead Candidate. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!